Royal Bank of Canada’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12M Sell
425,600
-199,400
-32% -$5.31M ﹤0.01% 1792
2025
Q4
$15.6M Sell
625,000
-659,900
-51% -$16.6M ﹤0.01% 1663
2025
Q3
$32.7M Buy
1,284,900
+73,300
+6% +$1.81M 0.01% 1268
2025
Q2
$29.4M Sell
1,211,600
-1,340,000
-53% -$31.3M 0.01% 1266
2025
Q1
$64.7M Buy
2,551,600
+294,800
+13% +$7.71M 0.01% 692
2024
Q4
$59.9M Buy
2,256,800
+2,196,800
+3,661% +$59.6M 0.01% 758
2024
Q3
$1.74M Hold
60,000
﹤0.01% 3093
2024
Q2
$1.68M Hold
60,000
﹤0.01% 3034
2024
Q1
$1.67M Sell
60,000
-76,100
-56% -$2.11M ﹤0.01% 3067
2023
Q4
$3.92M Buy
136,100
+37,400
+38% +$1.13M ﹤0.01% 2459
2023
Q3
$3.27M Buy
98,700
+25,000
+34% +$884K ﹤0.01% 2429
2023
Q2
$2.7M Buy
+73,700
New +$2.87M ﹤0.01% 2601
2023
Q1
Sell
-630,000
Closed -$32.3M 7376
2022
Q4
$32.3M Hold
630,000
0.01% 878
2022
Q3
$27.6M Hold
630,000
0.01% 888
2022
Q2
$33M Sell
630,000
-200,000
-24% -$10.2M 0.01% 832
2022
Q1
$43M Buy
830,000
+245,000
+42% +$12.7M 0.01% 818
2021
Q4
$34.5M Buy
585,000
+515,000
+736% +$25.5M 0.01% 1041
2021
Q3
$3.01M Hold
70,000
﹤0.01% 2741
2021
Q2
$2.74M Sell
70,000
-8,000
-10% -$311K ﹤0.01% 2785
2021
Q1
$2.83M Sell
78,000
-238,800
-75% -$8.48M ﹤0.01% 2729
2020
Q4
$11.7M Sell
316,800
-412,041
-57% -$15.1M ﹤0.01% 1604
2020
Q3
$25.4M Buy
728,841
+26,455
+4% +$928K 0.01% 942
2020
Q2
$21.8M Buy
702,386
+396,726
+130% +$13.5M 0.01% 990
2020
Q1
$9.47M Sell
305,660
-72,094
-19% -$2.46M ﹤0.01% 1384
2019
Q4
$14M Hold
377,754
0.01% 1378
2019
Q3
$12.9M Sell
377,754
-84,952
-18% -$3.09M 0.01% 1366
2019
Q2
$19M Buy
462,706
+122,686
+36% +$4.87M 0.01% 1124
2019
Q1
$13.7M Sell
340,020
-206,057
-38% -$8.25M 0.01% 1304
2018
Q4
$22.6M Buy
546,077
+41,316
+8% +$1.72M 0.01% 917
2018
Q3
$21.1M Sell
504,761
-120,261
-19% -$4.63M 0.01% 1097
2018
Q2
$21.5M Sell
625,022
-132,699
-18% -$4.53M 0.01% 1029
2018
Q1
$25.5M Sell
757,721
-382,180
-34% -$13.1M 0.01% 935
2017
Q4
$39.2M Buy
1,139,901
+191,301
+20% +$6.52M 0.02% 738
2017
Q3
$32.1M Sell
948,600
-110,670
-10% -$3.56M 0.02% 793
2017
Q2
$33.8M Buy
1,059,270
+537,540
+103% +$17M 0.02% 734
2017
Q1
$16.9M Sell
521,730
-1,964,656
-79% -$61.9M 0.01% 1133
2016
Q4
$76.6M Buy
2,486,386
+1,422,268
+134% +$43.4M 0.04% 368
2016
Q3
$34.2M Buy
1,064,118
+424,867
+66% +$14.2M 0.02% 681
2016
Q2
$21.4M Sell
639,251
-577,487
-47% -$18.4M 0.01% 915
2016
Q1
$34.2M Sell
1,216,738
-621,438
-34% -$17.8M 0.02% 624
2015
Q4
$56.3M Buy
1,838,176
+1,005,938
+121% +$31.6M 0.04% 401
2015
Q3
$24.8M Buy
832,238
+15,915
+2% +$510K 0.02% 653
2015
Q2
$26M Sell
816,323
-1,796,965
-69% -$58.6M 0.02% 674
2015
Q1
$86.3M Buy
2,613,288
+1,043,250
+66% +$33.2M 0.06% 227
2014
Q4
$46.4M Buy
1,570,038
+289,850
+23% +$8.31M 0.03% 442
2014
Q3
$35.9M Buy
1,280,188
+331,588
+35% +$9.31M 0.02% 504
2014
Q2
$26.7M Buy
+948,600
New +$27M 0.02% 638
2014
Q1
Sell
-368,900
Closed -$10.7M 6083
2013
Q4
$10.7M Buy
368,900
+115,940
+46% +$3.37M 0.01% 1155
2013
Q3
$6.89M Sell
252,960
-400,520
-61% -$10.9M 0.01% 1363
2013
Q2
$17.4M Buy
+653,480
New +$18.1M 0.01% 739

Other funds holding PFE

Royal Bank of Canada's PFE Position: Q1 2026 in Review

Royal Bank of Canada reduced its Pfizer (PFE) stake by 4.8% in Q1 2026, selling an estimated $45.6M and leaving 34,155,840 shares worth $959M. The position accounts for 0.17% of the portfolio, ranked #114.

Royal Bank of Canada first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.63B in Q4 2021. 2,946 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Royal Bank of Canada held 34,155,840 shares of Pfizer worth $959M as of Q1 2026.
  • Royal Bank of Canada sold 1,714,429 Pfizer shares in Q1 2026, an estimated $45.6M.
  • Pfizer made up 0.17% of Royal Bank of Canada's portfolio in Q1 2026, its #114 holding.
  • Royal Bank of Canada first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Pfizer position peaked at $1.63B in Q4 2021.
  • 2,946 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.